NO20004167L - Kaspase-8 interagerende proteiner - Google Patents

Kaspase-8 interagerende proteiner

Info

Publication number
NO20004167L
NO20004167L NO20004167A NO20004167A NO20004167L NO 20004167 L NO20004167 L NO 20004167L NO 20004167 A NO20004167 A NO 20004167A NO 20004167 A NO20004167 A NO 20004167A NO 20004167 L NO20004167 L NO 20004167L
Authority
NO
Norway
Prior art keywords
caspase
interacting proteins
interacting
proteins
Prior art date
Application number
NO20004167A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004167D0 (no
Inventor
David Wallach
Marcus Schuchmann
Tanya Goncharov
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12772198A external-priority patent/IL127721A0/xx
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO20004167D0 publication Critical patent/NO20004167D0/no
Publication of NO20004167L publication Critical patent/NO20004167L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01033—N-Acetylglucosamine deacetylase (3.5.1.33)
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
NO20004167A 1998-12-24 2000-08-21 Kaspase-8 interagerende proteiner NO20004167L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12772198A IL127721A0 (en) 1998-12-24 1998-12-24 Caspase-8 interacting proteins
IL13210599A IL132105A0 (en) 1998-12-24 1999-09-28 Caspase-8 interacting proteins
PCT/IL1999/000698 WO2000039160A2 (en) 1998-12-24 1999-12-23 Caspase-8 interacting proteins

Publications (2)

Publication Number Publication Date
NO20004167D0 NO20004167D0 (no) 2000-08-21
NO20004167L true NO20004167L (no) 2000-10-19

Family

ID=26323761

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004167A NO20004167L (no) 1998-12-24 2000-08-21 Kaspase-8 interagerende proteiner

Country Status (20)

Country Link
US (3) US6762283B1 (ja)
EP (1) EP1058691A1 (ja)
JP (1) JP2002536965A (ja)
KR (2) KR100646074B1 (ja)
CN (2) CN1223608C (ja)
AR (1) AR029321A1 (ja)
AU (1) AU780585B2 (ja)
BG (2) BG65375B1 (ja)
BR (1) BR9909252A (ja)
CA (1) CA2321672A1 (ja)
EA (2) EA005853B1 (ja)
EE (1) EE200000487A (ja)
HK (1) HK1037197A1 (ja)
HU (1) HUP0100671A3 (ja)
IL (3) IL132105A0 (ja)
NO (1) NO20004167L (ja)
NZ (1) NZ506477A (ja)
PL (1) PL350181A1 (ja)
SK (1) SK12682000A3 (ja)
WO (1) WO2000039160A2 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002103A (es) * 2001-09-04 2004-06-07 Yeda Res & Dev Una proteina de union a caspasa-8, su preparacion y uso.
US20040072770A1 (en) * 2002-07-03 2004-04-15 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-7 and 8
IL158599A0 (en) * 2003-10-26 2004-05-12 Yeda Res & Dev Methods of modulating hematopoiesis
JP5513130B2 (ja) * 2007-02-23 2014-06-04 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 金属タンパク質の活性を阻害するために有用な抗体および該抗体を含有する医薬組成物
US8809002B2 (en) * 2008-07-10 2014-08-19 Dana-Farber Cancer Institute, Inc. MUC1, caspase-8, and DED-containing proteins
JP6710680B2 (ja) 2014-09-04 2020-06-17 メモリアル スローン ケタリング キャンサー センター ヘモグロビン異常症を処置するためのグロビン遺伝子療法
CN104694485A (zh) * 2015-02-13 2015-06-10 广西壮族自治区兽医研究所 Z-ietd-fmk在提高prrsv体外培养滴度方面的应用及其方法
CN106146665B (zh) * 2016-08-31 2019-08-09 中国农业科学院植物保护研究所 一种用于制备针对甜菜夜蛾caspase-5大亚基的抗体的方法
JP2020510097A (ja) * 2017-03-16 2020-04-02 イミュンワーク インク．Ｉｍｍｕｎｗｏｒｋ Ｉｎｃ． リンカーユニット及びリンカーユニットを含む分子構築物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL94039A (en) * 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
JPH0625292A (ja) * 1990-10-31 1994-02-01 Mitsui Toatsu Chem Inc タンパク質及びその遺伝子
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
WO1993016178A2 (en) * 1992-02-12 1993-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
US5364503A (en) 1992-02-20 1994-11-15 Macmillan Bloedel Limited Nitric oxide treatment for ozone bleaching
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
IL104355A (en) * 1993-01-10 2006-08-20 Yeda Res & Dev Tnf receptor promoter
IL109633A (en) * 1994-05-11 2005-05-17 Yeda Res & Dev Tnf receptor promoter
JP2002514903A (ja) * 1996-06-17 2002-05-21 ジンザイム コーポレイション 新規のヒト第１６染色体遺伝子、組成物、それを作製および使用する方法
US6242569B1 (en) * 1997-02-05 2001-06-05 Tularik, Inc. Regulators of apoptosis
JP2003500002A (ja) * 1998-05-29 2003-01-07 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトヒドロラーゼ相同体：ｎ−末端アスパラギンアミドヒドロラーゼ、グリコシルヒドロラーゼ、グルコヒドロラーゼ、ビオチニダーゼ及びｎ−アセチルグルコサミン６−ｐデアセチラーゼ
US6326354B1 (en) * 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
CA2350415A1 (en) * 1998-11-18 2000-05-25 Incyte Pharmaceuticals, Inc. Inflammation-associated genes
EP1002900A1 (de) 1998-11-18 2000-05-24 SP Beton GmbH & Co. KG Verkehrsflächen-Bodenbelag mit Bodenbelagelementen aus Kunststeinmaterial

Also Published As

Publication number Publication date
IL132105A0 (en) 2001-03-19
KR100646075B1 (ko) 2006-11-15
BG65375B1 (bg) 2008-04-30
PL350181A1 (en) 2002-11-18
EE200000487A (et) 2002-02-15
KR20010041250A (ko) 2001-05-15
EP1058691A1 (en) 2000-12-13
NO20004167D0 (no) 2000-08-21
US6762283B1 (en) 2004-07-13
CN1298411A (zh) 2001-06-06
IL178921A0 (en) 2007-03-08
WO2000039160A2 (en) 2000-07-06
EA007273B1 (ru) 2006-08-25
KR20060090770A (ko) 2006-08-16
WO2000039160A3 (ja) 2001-08-23
AU1795000A (en) 2000-07-31
CN1603342A (zh) 2005-04-06
EA005853B1 (ru) 2005-06-30
US7339047B2 (en) 2008-03-04
HUP0100671A3 (en) 2006-04-28
NZ506477A (en) 2003-08-29
HUP0100671A2 (hu) 2001-06-28
BR9909252A (pt) 2000-11-28
AU780585B2 (en) 2005-04-07
JP2002536965A (ja) 2002-11-05
US20040229260A1 (en) 2004-11-18
BG109904A (bg) 2008-01-31
IL138025A (en) 2007-08-19
EA200401390A1 (ru) 2005-02-24
CA2321672A1 (en) 2000-07-06
EA200000875A1 (ru) 2001-10-22
HK1037197A1 (en) 2002-02-01
SK12682000A3 (sk) 2001-03-12
KR100646074B1 (ko) 2006-11-13
US20080139476A1 (en) 2008-06-12
AR029321A1 (es) 2003-06-25
BG104707A (en) 2001-04-30
CN1223608C (zh) 2005-10-19

Similar Documents

Publication Publication Date Title
NO982097L (no) Peptider
NO982098L (no) Peptider
DK1070058T3 (da) (4-Arylsulfonylamino)-tetrahydropyran-4-carboxylsyrehydroxamider
ATE341990T1 (de) Sigmidoskop
DE69920011D1 (de) Rekombinanter venezolanische-equine-pferdeenzephalitis-virusimpstoff
CY2006006I1 (el) Πρωτεϊνικα σκευασματα
ATE262513T1 (de) Benzoylpyridazine
NO20004167D0 (no) Kaspase-8 interagerende proteiner
ATE246494T1 (de) Brausezubereitungen
DE59903987D1 (de) Achsschenkel
DE59908817D1 (de) Wässrige zubereitungen
DE59901046D1 (de) Methylcyclotetradec-5-en-1-one
FR2791348B1 (fr) POLYPEPTIDE Npt2B
DE59807217D1 (de) Nadellager
DE1118098T1 (de) Mehrfachflussigelektrosprühschnittstelle
DE69925271D1 (de) Angiostatin-bindendes protein
DK1051487T3 (da) Placentaprotein 13
FI980759A0 (fi) Taetningskonstruktion foer suglaodan i en sugvals
DE59808995D1 (de) Endomikroskopsystem
DE19842103B4 (de) Stanznietzuführung
DE59900612D1 (de) Dispersionsazofarbstoffmischungen
PT1076660E (pt) (4-bromopirazol-3-il)-benzazolos substituidos
NO20012283D0 (no) Koblede peptider
ATA131698A (de) Gelenkanordnung
FR2784735B1 (fr) Raccord tournant

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application